AllSci News
Nxera Pharma licenses GPCR-targeted program to new co.
Nxera Pharma Co., Ltd. announced a GPCR licensing agreement with a newly established independent company created in partnership with a consortium of…
Novo Holdings joins European Life Sciences Coalition to tackle EU funding gap
Novo Holdings, the controlling shareholder in Denmark’s Novo Nordisk, announced its participation in the founding of the newly formed European Life Sciences…
Pfizer halts Phase I trial of Nxera-licensed MC4R antagonist in malnutrition research
Pfizer has terminated a Phase I clinical trial evaluating PF-07258669, an experimental drug targeting unintended weight loss in older adults, according to…
Nektar Therapeutics raises USD 400m in landmark public offering
Nektar Therapeutics (Nasdaq: NKTR), a San Francisco-based clinical-stage biotechnology company, announced a USD 400 million public offering on February 11, 2026. The…
Madrigal picks up Ribo Life Science’s siRNA therapeutics for MASH in USD 4.4b deal
Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) and its subsidiary Ribocure Pharmaceuticals AB announced an exclusive worldwide licensing agreement with Madrigal…
Keytruda takes landmark approval in ovarian cancer
The US FDA approved Keytruda (pembrolizumab) and Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) in combination with paclitaxel and bevacizumab for adult patients…
NYU researchers identify HOXD13 as dual driver of melanoma growth, immune evasion
Researchers at NYU Langone Health and its Perlmutter Cancer Center have identified a molecule that simultaneously fuels the growth of melanoma and…
Pfizer joins Swiss biotech accelerator BaseLaunch
Pfizer reportedly joined BaseLaunch, a Basel-based biotech venture incubator and accelerator, as its seventh global pharmaceutical partner. This partnership grants Pfizer strategic…
Galecto makes secondary offering for USD 27.5m
Denmark-based Galecto, Inc. (Nasdaq: GLTO) announced the pricing of an underwritten public offering with total gross proceeds of USD 27.5 million. The…
Moderna receives Refusal-to-File letter from FDA for mRNA flu vaccine mRNA-1010
Moderna gave notice that the US FDA’s Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for its investigational seasonal…
Leqembi subcutaneous formulation secures Priority Review for Alzheimer’s in China
Eisai and Biogen received a priority review award from China’s National Medical Products Administration (NMPA) for the subcutaneous formulation of Leqembi (lecanemab).…
Akeso moves first-in-class IL-4Rα/ST2 BsAb into Phase II for respiratory, autoimmune diseases
China-based Akeso Inc., (9926.HK) announced clearance from China’s National Medical Products Administration (NMPA) to initiate seven Phase II studies for its first-in-class…
Upstream Bio’s long-acting TSLP antibody set for Phase III after positive severe asthma trial
Upstream Bio announced positive top-line results from its Phase II VALIANT clinical trial evaluating verekitug asthma treatment, demonstrating statistically significant reductions in…
Pertussis vaccines firm ILiAD raises USD 115m in Series B
Weston, Florida-based ILiAD Biotechnologies, a clinical-stage biotechnology company focused on the prevention and treatment of diseases caused by Bordetella pertussis, has entered…
ProMIS Neurosciences raises USD 175m in private placement financing
ProMIS Neurosciences (Nasdaq: PMN) announced a private placement in public equity (PIPE) financing of up to approximately USD 175 million before fees…
The AllSci Brief
Systematic R&D and deal news. Daily.